Navigation Links
Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
Date:1/7/2008

- 85% of patients achieve undetectable HCV RNA levels following 4 weeks of treatment with R7128 1500mg and Pegasys(R) plus Copegus(R) with safety and

tolerability comparable to placebo -

- Conference Call Scheduled for 4:00PM ET Today -

PRINCETON, N.J., Jan. 7 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces the preliminary results of a 4-week Phase 1 clinical trial to evaluate two oral dose levels of R7128 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in 50 treatment-naive patients chronically infected with hepatitis C virus (HCV) genotype 1. In this study, R7128 demonstrated potent short-term antiviral activity and was generally safe and well-tolerated. Eighty-five (85%) of patients receiving R7128 1500mg and Pegasys plus Copegus achieved undetectable HCV RNA levels following 4 weeks of treatment with safety and tolerability comparable to placebo. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analogue polymerase inhibitor of HCV that is being developed through Pharmasset's collaboration with Roche.

Dr. Michelle Berrey, Pharmasset's Chief Medical Officer, stated "R7128, in combination with Pegasys plus Copegus, has shown that nucleoside polymerase inhibitors can demonstrate Rapid Virologic Response (RVR) percentages that are similar to protease inhibitors with an acceptable short-term clinical safety profile. This study also suggests that there appear to be certain synergies between nucleoside polymerase inhibitors and the standard of care that is not found with other classes of HCV inhibitors. The addition of R7128 at both dose levels to the current standard of care has demonstrated a greater percentage of RVR compared to the standa
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
2. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
3. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
4. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , N.J. and NEW PROVIDENCE, N.J. ... experts will present a paper on the critical ... medical oxygen storage and deliver systems at the American ... will be held at the Chicago Sheraton Hotel and ... Derrick West , program manager of ...
(Date:9/15/2014)...  Bayer HealthCare and Orion Corporation, a pharmaceutical ... , have begun to enroll patients in a ... androgen receptor inhibitor in clinical development. The study, ... prostate cancer who have rising Prostate Specific Antigen ... is designed to determine the effects of the ...
(Date:9/15/2014)... WALTHAM, Mass. , Sept. 15, 2014  Alere Inc. ... a global leader in infectious disease, toxicology, cardiology and ... of former executives, led by former CEO Ron ... and Exchange Commission and subsequently sent a letter to ... requesting one month of due diligence in an effort ...
Breaking Medicine Technology:Linde Healthcare experts to present details on installation of medical oxygen storage and distribution systems at ASPE convention 2Linde Healthcare experts to present details on installation of medical oxygen storage and distribution systems at ASPE convention 3Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3Alere Responds To Letter From Former Executives 2
... Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... has successfully completed the validation phase of the Unifill® ... final step in the industrialization process for the Unifill ... said: "The completion of all validation tests associated with ...
... Cayenne Medical, Inc., a private sports medicine device ... System, its second generation device for treatment of traumatic ... the 2011 American Orthopaedic Society for Sports Medicine Annual ... Tal David, MD, orthopedic sports medicine specialist, San ...
Cached Medicine Technology:Unilife Successfully Completes Industrialization of Unifill Syringe 2Unilife Successfully Completes Industrialization of Unifill Syringe 3Unilife Successfully Completes Industrialization of Unifill Syringe 4Cayenne Medical, Inc. Launches CrossFix® II Meniscal Repair System 2
(Date:9/16/2014)... is relative, especially to people who tend to be ... Medical Center in the US found that seven in ... People of normal weight make this mistake much less ... to misjudge their children,s size, as youngsters misjudge their ... at Weill-Cornell Medical College, in a study in the ...
(Date:9/16/2014)... study that compared patient-reported outcomes of a broad ... that single fraction radiation therapy (SFRT) is equally ... when pain, function and quality of life are ... American Society for Radiation Oncology,s (ASTRO,s) 56th Annual ... patients, pain, function and degree of distress were ...
(Date:9/16/2014)... While abnormalities in the adrenergic and noradrenergic systems, ... to play a role in the development of ... been no genetic evidence of this connection. A ... University,s Mailman School of Public Health and the ... ADRB2 gene and childhood adversity. For individuals with ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Beginning October 1st ... a new service offering for its clients who book a ... the volume of business they buy. Most recurring visit ... during the work week, but others include clients whose unique ... pet sitter on a daily basis. The newly ...
(Date:9/16/2014)... Philadelphia, PA (PRWEB) September 16, 2014 ... #1 Pain Management practice by Ranking Arizona magazine, has ... for implementation across its enterprise. , With TPC ... had a vast data repository that was managed through ... for both the management and clinical leadership teams. ...
Breaking Medicine News(10 mins):Health News:Poor body size judgement can lead to increased tolerance of obesity 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 3Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3
... , MORRISTOWN, N.J., Dec. 2 ... announced that the Federal Trade Commission (FTC) has accepted a ... acquisition of privately held Arrow Group and has granted early ... the parties to close the transaction. The parties have ...
... , NASHVILLE, Tenn., Dec. 2 ... company, has appointed Pearson Talbert as chief development officer. ... will provide leadership and vision to the sales and ... hospitals grow revenues through employer partnerships and physician relationships. ...
... , MORRISTOWN, N.J., Dec. 2 Watson Pharmaceuticals, Inc. (NYSE: ... the acquisition of Arrow Group for a combination of cash ... pharmaceutical company with over $3 billion in annual revenues and ... several significant benefits to Watson shareholders as a result of ...
... taking it for macular degeneration is not advised, ... Women who take low-dose aspirin to protect their heart ... new study by Harvard University researchers found what they ... age-related macular degeneration (AMD), an eye disease that destroys ...
... ... Lighting Sunday, December 13 to remember all children who died. Hundreds of services open to ... many believe is the world,s largest mass candle lighting. , ... Oak Brook IL (PRWEB) December 2, 2009 -- Tens of ...
... ... to do better, be better and take better self-care. What to do to ensure the ... make self-care the #1 priority. At Garden of Eve safe skin care is the primary ... consumer guide to safe cosmetic products. , ...
Cached Medicine News:Health News:Watson Receives FTC Clearance for Arrow Acquisition 2Health News:Aegis Health Group Hires Pearson Talbert as Chief Development Officer 2Health News:Watson Completes Acquisition of Arrow Group 2Health News:Watson Completes Acquisition of Arrow Group 3Health News:Watson Completes Acquisition of Arrow Group 4Health News:Watson Completes Acquisition of Arrow Group 5Health News:In Women, Aspirin Might Ward Off Eye Trouble 2Health News:Bereaved Families Unite for Compassionate Friends Worldwide Candle Lighting 2Health News:The New Year's Resolution that Fuels Them All: Self-Care; Garden of Eve Makes Self-Care Through Safe Skin Care # 1 Priority 2Health News:The New Year's Resolution that Fuels Them All: Self-Care; Garden of Eve Makes Self-Care Through Safe Skin Care # 1 Priority 3Health News:The New Year's Resolution that Fuels Them All: Self-Care; Garden of Eve Makes Self-Care Through Safe Skin Care # 1 Priority 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: